Literature DB >> 6189504

The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP).

M J Peckham, A Barrett, K H Liew, A Horwich, B Robinson, H J Dobbs, T J McElwain, W F Hendry.   

Abstract

Between July 1979 and December 1981, 43 patients with metastatic germ-cell tumours (36 testicular non-seminomas and 7 testicular seminomas) were treated with 2-6 cycles of bleomycin, etoposide and cis-platin (BEP). Forty (93%) are alive, 37 (86%) with no evidence of disease. Of 36 men with testicular non-seminoma 30 (83.3%) are alive and disease-free at 8-38 months (median 17.0 months). In the latter group 25/28 (89.3%) who had had no prior irradiation are alive and disease-free. Fourteen non-seminoma patients had small volume metastases and 13 are in complete remission, as are 12/14 patients with bulky disease. All 7 patients with advanced seminoma are alive and disease-free. It is concluded that BEP is a well tolerated and effective first line treatment for patients with metastatic germ-cell tumours.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6189504      PMCID: PMC2011384          DOI: 10.1038/bjc.1983.99

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  9 in total

1.  Combination chemotherapy in disseminated testicular cancer: the Indiana University experience.

Authors:  L H Einhorn; J P Donohue
Journal:  Semin Oncol       Date:  1979-03       Impact factor: 4.929

2.  Epipodophylin derivative (VP 16-23) in malignant teratomas and choriocarcinomas.

Authors:  E S Newlands; K D Bagshawe
Journal:  Lancet       Date:  1977-07-09       Impact factor: 79.321

3.  VP16-213 as a single agent in advanced testicular tumors.

Authors:  B M Fitzharris; S B Kaye; S Saverymuttu; E S Newlands; A Barrett; M J Peckham; T J McElwain
Journal:  Eur J Cancer       Date:  1980-09       Impact factor: 9.162

4.  A phase II study of oral VP-16-213 in non-seminomatous testicular cancer.

Authors:  F Cavalli; O Klepp; J Renard; M Röhrt; P Alberto
Journal:  Eur J Cancer       Date:  1981-02       Impact factor: 9.162

5.  Etoposide and etoposide-ifosfamide therapy for refractory testicular tumors.

Authors:  K Bremer; N Niederle; W Krischke; M Higi; M E Scheulen; C G Schmidt; S Seeber
Journal:  Cancer Treat Rev       Date:  1982-06       Impact factor: 12.111

Review 6.  Etoposide (VP-16-213).

Authors:  B F Issell; S T Crooke
Journal:  Cancer Treat Rev       Date:  1979-06       Impact factor: 12.111

7.  VP-16-213 salvage therapy for refractory germinal neoplasms.

Authors:  S D Williams; L H Einhorn; F A Greco; R Oldham; R Fletcher
Journal:  Cancer       Date:  1980-11-15       Impact factor: 6.860

8.  Chemotherapy of disseminated testicular cancer. A random prospective study.

Authors:  L H Einhorn; S D Williams
Journal:  Cancer       Date:  1980-09-15       Impact factor: 6.860

9.  Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer.

Authors:  L H Einhorn; J Donohue
Journal:  Ann Intern Med       Date:  1977-09       Impact factor: 25.391

  9 in total
  34 in total

Review 1.  Regular review: Managing testicular cancer.

Authors:  D Dearnaley; R Huddart; A Horwich
Journal:  BMJ       Date:  2001-06-30

2.  Brain metastasis from non-seminomatous germ cell tumors of the testis: indications for aggressive treatment.

Authors:  Maurizio Salvati; Manolo Piccirilli; Antonino Raco; Antonino Santoro; Riccardo Frati; Jacopo Lenzi; Gaetano Lanzetta; Antonino Agrillo; Alessandro Frati
Journal:  Neurosurg Rev       Date:  2005-11-23       Impact factor: 3.042

Review 3.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

4.  Chemotherapy for non-seminomatous germ-cell tumours.

Authors:  P M Wilkinson
Journal:  J R Soc Med       Date:  1985       Impact factor: 5.344

5.  Testicular germ cell tumours--a model for a new approach to treatment of adult solid tumours.

Authors:  R T Oliver
Journal:  Postgrad Med J       Date:  1985-02       Impact factor: 2.401

6.  Rare cancers and specialist centres.

Authors:  R T Oliver
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-08

7.  A case of immature teratoma originating in intra-abdominal undescended testis in a 3-month-old infant.

Authors:  Tomomi Hasegawa; Kosaku Maeda; Naoki Kamata; Yutaka Okita
Journal:  Pediatr Surg Int       Date:  2006-05-13       Impact factor: 1.827

8.  Significance of presence of teratomatous elements in the primary tumour of testicular cancer.

Authors:  K Suzuki; H Nakazato; K Matsumoto; K Kurokawa; T Suzuki; K Suzuki; H Yamanaka
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

9.  Exploring the spectrum of late effects following radical orchidectomy for stage I testicular seminoma: a systematic review of the literature.

Authors:  Jennifer A Soon; Angelyn Anton; Javier Torres; Ruth Lawrence; Phillip Parente; Joseph McKendrick; Ian D Davis; Carmel Pezaro
Journal:  Support Care Cancer       Date:  2018-10-22       Impact factor: 3.603

Review 10.  [Testis cancer: the UK as a model].

Authors:  S B Maddineni; N W Clarke
Journal:  Urologe A       Date:  2009-04       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.